Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Lebwohl

Showing results (161-170 of 209) with videos related to

Pageof 21
Sort By:
JAMA Dermatology|May 14, 2015
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Robert E Kalb, David F Fiorentino, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology|July 7, 2019
Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trialPeter W Hashim, Margot Chima, Hee J Kim, et al.
Journal of the American Academy of Dermatology|February 9, 2016
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])Bruce E Strober, Robert Bissonnette, David Fiorentino, et al.
Allergy|August 30, 2021
Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patientsEmma Guttman-Yassky, Yael Renert-Yuval, Jennifer Bares, et al.
American Journal of Clinical Dermatology|July 29, 2025
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial ResultsKim A Papp, Mark G Lebwohl, Lluís Puig, et al.
Lancet (London, England)|September 22, 2023
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trialAkimichi Morita, Bruce Strober, A David Burden, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 15, 2022
Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic DermatitisKristian Reich, Peter A Lio, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|May 23, 2026
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD StudyJennifer Soung, Yong Cui, Robert Bissonnette, et al.
The Journal of Investigative Dermatology|July 14, 2024
Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1Ahmed Farag, Sudha Visvanathan, Hervé Bachelez, et al.
BMJ Open|March 31, 2021
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flareSiew Eng Choon, Mark G Lebwohl, Slaheddine Marrakchi, et al.
Pageof 21

Showing results (161-170 of 209) with videos related to

Sort By:
Pageof 21
JAMA Dermatology|May 14, 2015
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Robert E Kalb, David F Fiorentino, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology|July 7, 2019
Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trialPeter W Hashim, Margot Chima, Hee J Kim, et al.
Journal of the American Academy of Dermatology|February 9, 2016
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])Bruce E Strober, Robert Bissonnette, David Fiorentino, et al.
Allergy|August 30, 2021
Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patientsEmma Guttman-Yassky, Yael Renert-Yuval, Jennifer Bares, et al.
American Journal of Clinical Dermatology|July 29, 2025
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial ResultsKim A Papp, Mark G Lebwohl, Lluís Puig, et al.
Lancet (London, England)|September 22, 2023
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trialAkimichi Morita, Bruce Strober, A David Burden, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 15, 2022
Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic DermatitisKristian Reich, Peter A Lio, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|May 23, 2026
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD StudyJennifer Soung, Yong Cui, Robert Bissonnette, et al.
The Journal of Investigative Dermatology|July 14, 2024
Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1Ahmed Farag, Sudha Visvanathan, Hervé Bachelez, et al.
BMJ Open|March 31, 2021
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flareSiew Eng Choon, Mark G Lebwohl, Slaheddine Marrakchi, et al.
Pageof 21